![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Resistance Analysis of Treatment-Experienced Genotype 1 and 3 HCV-Infected Patients Treated With Sofosbuvir in Combination With GS-5816 ± Ribavirin for 12 Weeks
|
|
|
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Brian P. Doehle,1 Evguenia S. Svarovskaia,1 Krishna Chodavarapu,1 John McNally,1 Stephen Pianko,2 Stuart K. Roberts,3 Diana M. Brainard,1 Michael D. Miller,1 Hongmei Mo1
1Gilead Sciences, Inc., Foster City, California, USA; 2Monash Health and Monash University, Clayton, Victoria, Australia; 3Alfred Health and Monash University, Melbourne, Victoria, Australia
![EASL1.gif](../images/050415/050415-3/EASL1.gif)
![EASL2.gif](../images/050415/050415-3/EASL2.gif)
![EASL3.gif](../images/050415/050415-3/EASL3.gif)
![EASL4.gif](../images/050415/050415-3/EASL4.gif)
![EASL5.gif](../images/050415/050415-3/EASL5.gif)
![EASL6.gif](../images/050415/050415-3/EASL6.gif)
![EASL7.gif](../images/050415/050415-3/EASL7.gif)
![EASL8.gif](../images/050415/050415-3/EASL8.gif)
![EASL9.gif](../images/050415/050415-3/EASL9.gif)
![EASL10.gif](../images/050415/050415-3/EASL10.gif)
![EASL11.gif](../images/050415/050415-3/EASL11.gif)
References
1. Jacobson IM, et al. N Engl J Med 2013;368:1867-77;
2. Lawitz E, et al. N Engl J Med 2013;368:1878-87;
3. Cheng G, et al. EASL 2013, poster 1191;
4. German P, et al. EASL 2013, poster 1195;
5. Lawitz E, et al. EASL 2013, poster 1082;
6. Pianko S, et al. AASLD 2014, oral 197.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|